AlgiPharma presenting at Formulation and Delivery 2024, London, UK

AlgiPharma presenting at Formulation and Delivery 2024, London, UK

We are delighted to have been invited to speak at the Formulation & Delivery 2024 conference, taking place 25th – 26th April in London, UK.

AlgiPharma will have two separate presentations highlighting it’s alginate technology for use in the drug delivery of lipid nanoparticles by inhalation and for oral uptake of peptides. Presentations will be by our Chief Scientific Officer, Dr. Philip Rye, and Chief Medical Officer, Dr. Yngve Mikkelsen.

Join us in London next week or follow up with us directly to get a copy of the presentations and explore commercial opportunities.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

 

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma is recruiting again!

R&D Project Manager at AlgiPharma

Application Deadline:  28.01.2024

The candidate will proactively manage the day-to-day running of multiple R&D projects, coordinating with key internal and external stakeholders to advance our portfolio of alginate oligosaccharide technologies for drug delivery, drug conjugates and stand-alone API for cystic fibrosis, COPD and infectious diseases. In addition to the basic project management activities, the candidate will also focus on the R&D development, formulation, and manufacturing elements of these projects in cooperation with internal and external parties, both nationally and internationally. The candidate will work collaboratively with multi-faceted teams including external academic and commercial CROs and suppliers. The candidate will have demonstrated clear organizational skills and experience of project management in the biotech/biopharma industry and have relevant experience in R&D and chemical/biotechnological manufacturing. Previous experience establishing effective working relationships in a virtual organization is an asset. The candidate will report directly to the Chief Scientific Officer.

The ideal candidate has:

  • PhD in chemical/biotechnological science or related field.
  • 5+ years’ experience of project management in the biotechnology or pharmaceutical industry.
  • Experience and a successful track record in managing multiple project accounts and familiarity applying to national and international funding agencies and reporting on project grants.
  • Proficiency in Microsoft Office programs and tools.
  • Excellent communication and presentation skills in Norwegian and English.
  • Having studied or worked outside Norway for at least a year is an advantage.

 

About AlgiPharma

AlgiPharma is a clinical stage biopharmaceutical company with a focus on developing its proprietary alginate technology for:

  • Drug delivery – technology platform for small and large molecule-based drugs.
  • Drug conjugates – adding functionality and reducing toxicity of the parent compound.
  • Stand-alone API – for respiratory diseases such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical-scale production capabilities and a broad family of patents protects its technology.

AlgiPharma aims to address unmet medical needs and fight diseases effectively through innovative alginate technologies. Our alginate technology targets diseases with a clinical need to mitigate abnormal mucus accumulation, non-invasive drug delivery challenges, microbial infection, biofilm formation and antibiotic resistance.

AlgiPharma has orphan drug status with EMA and FDA and has secured up to USD 47 million in non-dilutive funding from government and NGO support including NOK 150 million from the American Cystic Fibrosis Foundation in developing its first drug candidate for people with CF.

AlgiPharma has completed six clinical trials, showing exemplary safety and tolerability.

AlgiPharma technology has a wide range of disease applications with particular emphasis on inhalation and oral drug delivery.

Building on the success and recent developments of the technology, the team at AlgiPharma is expanding to meet the demands of significant external interest in our technology.

 

What AlgiPharma offers

  • An engaging and dynamic working environment at a company that has multiple commercial development opportunities.
  • Opportunity for self-development, such as training courses and conference.
  • Flexible working hours to maintain a good work-life balance.
  • Senior management health insurance plan for all.
  • Excellent remuneration.

 

We are interested in hearing from high caliber, energetic candidates to join the AlgiPharma team at our Norwegian office in Sandvika. Preference will be given to those candidates already resident in Norway or who are already eligible to work in Norway.

 

Please address questions regarding the position to:

Mr. Arne Dessen, COO / Chairman  BoD, arne.dessen@algipharma.com,